CARB-X FUNDS INTEGRATED BIOTHERAPEUTICS TO EXPAND THE DEVELOPMENT OF ITS STAPHYLOCOCCUS AUREUS VACCINE TO FACILITATE USE IN THE DEVELOPING WORLDHaimi Shiferaw2020-11-01T17:51:57+00:00July 1st, 2019|Read More
IBT Receives Phase II STTR grant from NIAID for development of Novel ISTAb therapeutics for B. anthracisHaimi Shiferaw2020-11-01T17:50:56+00:00July 1st, 2019|Read More
IBT Receives Phase I SBIR grant from NIAID for development of monoclonal antibodies against Marburg Virus using a novel discovery platformHaimi Shiferaw2020-11-01T17:50:31+00:00March 1st, 2019|Read More
Potent Neutralization of Staphylococcal Enterotoxin B In Vivo by Antibodies that Block Binding to the T-Cell ReceptorHaimi Shiferaw2020-11-01T18:24:02+00:00October 30th, 2020|Read More
Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune EvasionHaimi Shiferaw2020-11-01T18:25:12+00:00October 29th, 2020|Read More
IBT Receives Phase I SBIR grant from NIAID for development of neutralizing monoclonal antibodies against Marburg VirusHaimi Shiferaw2020-11-01T17:49:14+00:00July 12th, 2019|Read More
IBT Receives Phase II STTR grant from NIAID for development of Novel ISTAb therapeutics for B. anthracisHaimi Shiferaw2020-11-01T17:14:30+00:00July 1st, 2019|Read More
IBT Receives Phase I SBIR grant from NIAID for development of monoclonal antibodies against Marburg Virus using a novel discovery platformHaimi Shiferaw2020-11-01T17:14:04+00:00March 1st, 2019|Read More
